Arylsulfatase D (ARSD)

Arylsulfatase D (ARSD) is a lysosomal enzyme of the sulfatase family encoded on the X chromosome (Xp22.3), involved in the hydrolysis of sulfate esters and crucial for correct composition of bone and cartilage matrix[1][2][3]. ARSD is post-translationally glycosylated and its gene frequently escapes X inactivation, resulting in higher expression especially in certain cancer subtypes[1][3]. In cancer, ARSD has context-dependent roles: its expression is associated with favorable prognosis in breast cancer (especially luminal subtypes) and is repressed in aggressive subtypes such as triple-negative breast cancer[1][3]. ARSD inhibits proliferation and migration of cancer cells by activating the Hippo/YAP pathway[1][3]. In glioma, ARSD promotes progression by enhancing proliferation, migration, and macrophage (M2) infiltration, with its effects mediated partly via the JAK2/STAT3 signaling pathway[2]. Elevated ARSD in chronic lymphocytic leukemia is associated with a more aggressive disease course[1]. ARSD therefore serves both as a biomarker and a potential therapeutic target in oncology[1][2][3].

Other names

ARSDASDarylsulfatase DArylsulfatase D, testis tissue sperm-binding protein Li 39a

Inhibition of JAK2/STAT3 pathway (by drugs such as AG490) can counteract ARSD-induced glioma cell proliferation, migration, and invasion[2]; Potential target for modulating Hippo/YAP pathway in cancer cells[1][3]